Veterinary Diagnostics Technology Roadmap¶
Veterinary diagnostics has followed a clear technological trajectory — from qualitative chemistry to instrumented quantitative POCT. This page maps that roadmap and where FICT sits.
The Evolution¶
| Generation | Technology | Readout | Status |
|---|---|---|---|
| 1 | Colloidal-gold strip | Visual (qualitative) | Commodity |
| 2 | Fluorescence POCT (FICT) | Instrument (quantitative) | Growing |
| 3 | Molecular POCT (PCR) | Instrument (nucleic acid) | Emerging |
| 4 | Multiplex / AI-assisted | Multi-analyte + software | Early |
Where FICT Sits¶
FICT (generation 2) is the current workhorse of quantitative POCT — it delivers laboratory-grade sensitivity with same-visit turnaround, without the cost and complexity of molecular POCT.
The Multiplex Direction¶
The next frontier is multiplexing — running multiple analytes from a single sample. The six-channel FIA880 is an early expression of this direction (mixed panels in one cycle).
Key Technology Levers¶
| Lever | Trend |
|---|---|
| Sensitivity | pg/ml → sub-pg/ml |
| Multiplexing | Single → multi-analyte panels |
| Connectivity | Standalone → cloud-synced (curves, records) |
| AI interpretation | Manual → assisted trend analysis |
FAQ¶
Will molecular POCT replace immunoassay? No — they answer different questions (nucleic acid vs protein/hormone) and will coexist, as they do in human medicine.
What is Migibio's roadmap focus? Deepening the quantitative immunoassay menu and multiplexing via the multi-channel platform.
For the market context, see Veterinary POCT Market.
Authored by: Migibio Clinical & Scientific Affairs, Guangzhou Magic Biotech Co., Ltd.
Reviewed by: Migibio R&D Quality Committee
Last updated: 2026-08-13
Disclosure: Migibio (Guangzhou Magic Biotech Co., Ltd.) is the manufacturer of the FIA680/FIA880 analyzers and FICT reagents referenced in this content. See our Editorial & Review Policy.